文献速递支持与姑息治疗乳腺癌

低剂量与标准剂量奥氮平联合三联止吐方案预防实体瘤高致吐化疗所致恶心呕吐:单中心、开放标签、非劣效性、随机对照3期试验

Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2024-01-12

该单中心开放标签非劣效性3期试验在印度纳入275例接受多柔比星-环磷酰胺或大剂量顺铂的实体瘤患者,比较低剂量(2.5 mg)与标准剂量(10.0 mg)奥氮平联合三联止吐方案的疗效。mITT人群267例中,2.5 mg组完全控制率45% vs 10.0 mg组44%(差异-1.0%,单侧95%CI -100.0至9.0),达到非劣效;2.5 mg组日间嗜睡显著减少。作者认为2.5 mg奥氮平可作为新的标准治疗。

要点

  • 低剂量奥氮平2.5 mg在总体期完全控制率上非劣效于10.0 mg(差异-1.0%,单侧95%CI -100.0至9.0)。
  • 2.5 mg组任何级别日间嗜睡65% vs 10.0 mg组90%(p<0.0001),严重嗜睡第1天5% vs 40%(p<0.0001)。
  • 作者认为2.5 mg奥氮平应被视为新的标准治疗。

核心结论

  • 作者认为,2.5 mg奥氮平在止吐疗效上非劣效于10.0 mg,且减少日间嗜睡发生,应被视为新的标准治疗。

研究设计与样本

  • 单中心、开放标签、非劣效性、随机对照3期试验,在印度孟买Tata Memorial Centre进行。
  • 纳入13-75岁、ECOG体能状态0-2、接受多柔比星-环磷酰胺或大剂量顺铂的实体瘤患者,随机1:1分组。
  • 低剂量组口服奥氮平2.5 mg每日一次,标准剂量组10.0 mg每日一次,均连用4天,联合三联止吐方案。
  • 主要终点为总体期(0-120小时)完全控制,在mITT人群(267例)中评估;非劣效界值为10%。

主要发现

  • mITT人群中2.5 mg组完全控制59/132(45%)vs 10.0 mg组59/135(44%),差异-1.0%(单侧95%CI -100.0至9.0),p=0.87。
  • 2.5 mg组任何级别日间嗜睡86/132(65%)vs 10.0 mg组121/135(90%),p<0.0001。
  • 第1天严重日间嗜睡2.5 mg组6/132(5%)vs 10.0 mg组54/135(40%),p<0.0001。

关键数值与推荐

  • 完全控制定义为无呕吐事件、无挽救药物、无或轻度恶心。
  • 非劣效性判定标准为完全控制率差异的单侧95%CI上限排除10%的非劣效界值。

临床怎么用

  • 作者认为,2.5 mg奥氮平应被视为接受高致吐化疗患者新的标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Olanzapine is an effective antiemetic agent but it results in substantial daytime somnolence when administered at the standard dose. Our aim was to compare the efficacy of low-dose versus standard-dose olanzapine after highly emetogenic chemotherapy in patients with solid tumours. METHODS: This was a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial done in a tertiary care referral centre in India (Tata Memorial Centre, Homi Bhabha National Institute, Mumbai). Patients aged 13-75 years with an Eastern Cooperative Oncology Group performance status of 0-2, who were receiving doxorubicin-cyclophosphamide or high-dose cisplatin for a solid tumour were eligible. Patients were randomly assigned (1:1), with block randomisation (block sizes of 2 or 4) and stratified by sex, age (≥55 or <55 years), and chemotherapy regimen, to receive low-dose (2·5 mg) oral olanzapine or standard-dose (10·0 mg) oral olanzapine daily for 4 days, in combination with a triple antiemetic regimen. Study staff were masked to treatment allocation but patients were aware of their group assignment. The primary endpoint was complete control, defined as no emetic episodes, no rescue medications, and no or mild nausea in the overall phase (0-120 hours), assessed in the modified intention-to-treat (mITT) population (ie, all eligible patients who received protocol-specified treatment, excluding those who had eligibility violations and who withdrew consent after randomisation). Daytime somnolence was the safety endpoint of interest. Non-inferiority was shown if the upper limit of the one-sided 95% CI for the difference in the complete control proportions between the treatment groups excluded the non-inferiority margin of 10%. This study is registered with the Clinical Trial Registry India, CTRI/2021/01/030233, is closed to accrual, and this is the final data analysis. RESULTS: Between Feb 9, 2021, and May 30, 2023, 356 patients were pre-screened for eligibility, of whom 275 patients were enrolled and randomly assigned (134 to the 2·5 mg olanzapine group and 141 to the 10·0 mg olanzapine group). 267 patients (132 in the 2·5 mg group and 135 in the 10·0 mg group) were included in the mITT population, of whom 252 (94%) were female, 15 (6%) were male, and 242 (91%) had breast cancer. 59 (45%) of 132 patients in the 2·5 mg olanzapine group had complete control in the overall phase versus 59 (44%) of 135 in the 10·0 mg olanzapine group (difference -1·0% [one-sided 95% CI -100·0 to 9·0]; p=0·87). In the overall phase, there were significantly fewer patients in the 2·5 mg olanzapine group than in the 10·0 mg olanzapine group with daytime somnolence of any grade (86 [65%] of 132 vs 121 [90%] of 135; p<0·0001) and of severe grade on day 1 (six]5%] vs 54 [40%]; p<0·0001). INTERPRETATION: Our findings suggest that olanzapine 2·5 mg is non-inferior to 10·0 mg in antiemetic efficacy and results in reduced occurrence of daytime somnolence among patients receiving highly emetic chemotherapy and should be considered as a new standard of care. FUNDING: Progressive Ladies Welfare Association.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Bajpai J, Kapu V, Rath S, et al. Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2024. PMID: 38224701. doi:10.1016/S1470-2045(23)00628-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。